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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the efficacy and safety of cough augmentation techniques in adults and children with chronic NMD and respiratory muscle
weakness.
B A C K G R O U N D
Description of the condition
There are a range of chronic neuromuscular disorders (NMDs)
in adults and children, including muscular dystrophies, congeni-
tal and metabolic myopathies, neuromuscular junction disorders,
peripheral neuropathies, and anterior horn cell diseases (Gozal
2000). People affected by chronic NMDs are at risk of progressive
respiratory insufficiency (breathing difficulties that worsen over
time), primarily from a combination of respiratory muscle weak-
ness and chest wall abnormalities (Boitano 2006; Finder 2010;
Gozal 2000; Panitch 2009).
Infants with NMD generally have normal lungs and normal mu-
cociliary clearance mechanisms at birth, although pulmonary me-
chanics may be affected from baseline, depending on the under-
lying NMD. Progressive respiratory insufficiency occurs with ad-
vancing age. Chest deformities may develop from infancy because
of respiratory muscle weakness and chronic paradoxical breathing
patterns, in conjunction with an initially very compliant chest wall
(Panitch 2009; Papastamelos 1996). Respiratory muscle weakness
causes chronic shallow breathing; the inability to sigh or yawn,
which is required to maintain full lung expansion; an ineffective
cough with secretion retention; and progressive loss of lung com-
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pliance (Fauroux 2008; Panitch 2009). Progressive thoracic defor-
mities such as scoliosis, kyphosis and spinal rigidity, together with
fibrosis of the intercostal muscles, further impact on lung function
with a progressive decrease in chest wall compliance and ultimately
a restrictive pattern of lung disease (Fauroux 2008; Gozal 2000;
Panitch 2009). Bulbar weakness and glottic dysfunction, as seen
in people with spinal muscular atrophy Type 1 and amyotrophic
lateral sclerosis/motor neuron disease (ALS/MND), also impact
on the ability to cough effectively (Boitano 2006; Chatwin 2018;
Toussaint 2018).
An effective cough is essential to clear pulmonary secretions. If
the cough is ineffective, as is the case in people with NMD and
respiratory weakness, long-term retention of secretions leads to
a vicious cycle of obstruction, infection, inflammation, increased
work of breathing, recurrent acute respiratory tract infections, and
ultimately chronic lung disease and respiratory failure (Chatwin
2018; Homnick 2007). Respiratory tract infection with altered
sputum viscosity and volume, difficulty swallowing (dysphagia),
and gastro-oesophageal reflux can all exacerbate secretion retention
in people with NMD and respiratory muscle weakness (Finder
2010; Iannaccone 2007).
An effective cough requires: a sufficiently deep inspiration; closure
of the glottis with simultaneous contraction of expiratory respira-
tory muscles to increase intrathoracic pressure; then abrupt open-
ing of the glottis at the start of the expiratory phase to produce a
rapid, forceful flow of air from the lungs (Boitano 2006; Chatwin
2018; Toussaint 2018). Any or all of these components may be
affected in a personwith NMD (Bach 2003; Boitano 2006; Finder
2010; Rokadia 2015).
Bach 1996 suggested that adults require a peak expiratory cough
flow (PCF) of 160 L/min for an effective cough. Adults have a
normal PCF of 360 L/min to 840 L/min (Leiner 1963; Tzeng
2000). Furthermore, it has been suggested that adults with NMD
require a PCF of more than 270 L/min when well, to account for
the expected decline in cough flows during intercurrent respiratory
infections (Bach 1997). Normal PCF values in children have been
published (Bianchi 2008). In children with NMD, an absolute
PCF of less than 160 L/min has been shown to be predictive of
severe disease, but age or size-adjusted reference values are not
available (Dohna-Schwake 2006), and it must be noted that the
normal range of PCF in young children is highly variable, with
healthy children only able to achieve PCFs of 160L/min on the
5th percentile by six years of age (Bianchi 2008). Therefore, for
children over the age of 12 years (when children attain adult PCF
(Bianchi 2008)), use of adult values for absolute PCF cut-offs may
be appropriate (Hull 2012). Further research to determine age-
adjusted PCF is warranted.
Most episodes of respiratory failure in people with NMD are likely
to be caused by ineffective coughing during intercurrent chest in-
fections (Bach 2003; Chatwin 2018). The identification of the
most effective, safe measures to optimise cough efficacy and pro-
mote secretion clearance is therefore vital to optimising pulmonary
function, preventing morbidity and improving the quality of life
in people with chronic NMD (Toussaint 2018).
Description of the intervention
Many airway clearance techniques are used in clinical practice in
people with NMD. Some techniques aim to move secretions from
the peripheral to the more central airways (secretion mobilisa-
tion techniques), whilst others aim to clear secretions from the
central airways (cough augmentation techniques) (Chatwin 2018;
Toussaint 2018). Secretion mobilisation and an effective cough
are both needed for effective secretion clearance (Finder 2010).
Manual techniques to assist peripheral secretion mobilisation in
adults and children with chronic NMD include positioning, chest
wall shaking, percussion and vibrations (Chatwin 2018; Toussaint
2018). Other secretion mobilisation techniques that have been
suggested for use in people with NMD include breathing exercises
(e.g. active cycle of breathing technique, forced expiratory tech-
nique, autogenic drainage, positive pressure therapy, oscillatory
positive pressure therapy); intermittent positive pressure breath-
ing; chest wall strapping; intrapulmonary percussive ventilation;
and high-frequency chest wall oscillation (Anderson 2005; Bott
2009; Chatwin 2018; Douglas 1981; Finder 2010; Hull 2012;
Toussaint 2018). Active breathing exercises are effort dependent
and therefore may not be useful in people with severe respiratory
muscle weakness (Finder 2010; Hull 2012), unless concomitant
ventilatory support is given (Chatwin 2018; Toussaint 2018).
Cough augmentation for proximal secretion clearance can be per-
formed using manual or mechanical methods, alone or in combi-
nation, to support different components of the cough (Chatwin
2018; Finder 2010; Toussaint 2018). Techniques such as breath or
air stacking, glossopharyngeal breathing and mechanical or man-
ual (bagging) single-breath insufflations, augment inspiration in
order to achieve sufficient inspiratory lung volumes before a cough
(Bott 2009; Chatwin 2018; Toussaint 2018). People can achieve
lung insufflation using positive pressure devices including venti-
lators (invasively or noninvasively) and intermittent positive pres-
sure breathing (IPPB) devices, with set pressure or volume limits,
or both. They may achieve breath or air stacking independently
(with glottic closure) or through use of an external self-inflating
manual resuscitator bag with a one-way valve, if needed, to pre-
vent air leak (Chatwin 2018; Toussaint 2018). For breath stacking,
a person takes or receives multiple inspiratory breaths, without
exhalation between breaths, until they achieve maximal insuffla-
tion capacity (MIC) (Bach 2007; Chatwin 2018; Marques 2014;
Toussaint 2018). Thereafter, the individual releases the breath in
a spontaneous or assisted forced expiratory manoeuvre or cough
(Chatwin 2018; Marques 2014). MIC refers to the maximum tol-
erable inspiratory lung volume (Bach 2007; Chatwin 2018; Kang
2000). Glossopharyngeal breathing or ’frog breathing’, which does
not use any external equipment, requires the person withNMD to
actively ’gulp’ air into the lungs until MIC is reached, using glottic
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closing and opening (Bach 2007; Chatwin 2018; Nygren-Bonnier
2009; Toussaint 2018).
Mechanical exsufflation and manually assisted cough (MAC), in
which the thorax or abdomen or both are manually compressed,
aim to improve expiratory flow rates by rapidly increasing intra-
abdominal or intrathoracic pressure, or both (Anderson 2005;
Chatwin 2018; Finder 2010; Toussaint 2018).
Mechanical insufflation-exsufflation (MI-E) supports both insuf-
flation and exsufflation, using a device which delivers a preset pos-
itive pressure into the airways for a set duration during inspira-
tion (insufflation), immediately followed by an abrupt change to
a preset negative exsufflation pressure, thereby simulating a cough
with high expiratory flow rates (Anderson 2005; Chatwin 2018;
Fauroux 2008; Morrow 2013; Toussaint 2018).
How the intervention might work
Both inspiratory and expiratory cough augmentation techniques
aim to optimise cough efficacy by improving PCF when respira-
tory muscles are too weak to independently achieve sufficient flow
rates for secretion clearance. The mechanism by which PCF is af-
fected differs amongst different cough augmentation techniques
(Chatwin 2018; Toussaint 2018).
Inspiratory cough augmentation techniques aim to augment in-
spiratory lung volumes to those required for an effective cough
(maximal insufflation capacity). By increasing inspiratory volume,
these techniques enhance expiratory flow bias during a sponta-
neous or assisted cough, thereby effectively mobilising secretions
(Chatwin 2018). Inhaling a large volume of air before the com-
pressive and expiratory phases of the cough optimises the length-
tension relationship of expiratory muscles and generates higher
intrathoracic pressures and PCF (Boitano 2006; Chatwin 2018).
Expiratory cough augmentation techniques, whether manual or
mechanical, aim to assist theweak expiratorymuscles in generating
sufficient intra-abdominal and intrathoracic pressures or increase
the expiratory flow generated during the cough, or both. The
overall aim is to increase PCF enough to effectively clear secretions
from the central airways (Boitano 2006; Chatwin 2018; Toussaint
2018).
Some investigators have suggested that combining inspiratory and
expiratory cough augmentation techniques could optimise cough
clearance in people with NMD (Boitano 2006; Chatwin 2018;
Hull 2012; Sivasothy 2001; Trebbia 2005; Toussaint 2018).
Why it is important to do this review
Cough augmentation techniques are essential to prevent progres-
sion to respiratory failure in people with NMD (Bach 2003;
Chatwin 2018); however, it is still unclear what technique/s offer
the most clinical benefit with the least risk of harm.
Any application of positive pressure to the lungs carries a risk
of complications including abdominal distention, discomfort,
gastro-oesophageal reflux, cardiovascular effects such as changes
in blood pressure and cardiac arrhythmia, and pneumothorax
(Chatwin 2018; Homnick 2007; Morrow 2013; Toussaint 2018).
Pneumothorax has been described in adults following the use of
MI-E (Suri 2008) and long-term non-invasive positive pressure
ventilation (Vianello 2004). There may be greater risk of baro-
trauma and volutrauma in infants and young children with NMD
compared to older children or adults, considering their different
respiratory anatomy and physiology. Application of positive pres-
sure will affect the lungs differently according to, for example, type
of lung disease, lung volumes, and respiratory system compliance
and resistance, all of which vary with age and NMD condition
(Gattinoni 2003; Gattinoni 2010). The effects of MAC may be
altered by chest wall compliance, which is almost twice that of
controls in infants with NMD (Papastamelos 1996), and may be
substantially reduced in adults with NMD (Gozal 2000; Panitch
2009). During MI-E specifically, applied insufflation volume is
not usually measured in clinical practice, and a rapid swing to
negative pressure follows insufflation. The combination of high
applied tidal volume together with atelectrauma associated with
repeated expansion and collapse of lung units has been associated
with lung injury in the context of invasive mechanical ventilation
(Albuali 2007; Saharan 2010). The safety of MI-E is not clear in
this regard.
Some cough augmentation techniques recommended in interna-
tional guidelines for the treatment of people with NMD require
equipment or expertise that are not readily available in lower-re-
sourced environments (Bott 2009; Chatwin 2018; Finder 2004;
McCool 2006; Rosière 2009; Toussaint 2018; Wang 2007; Wang
2010), whilst cheaper and more readily available techniques may
be equally effective (Anderson2005; Finder 2010).Currently, peo-
ple living with NMD and their caregivers generally manage their
airway clearance according to perceived need, and clinical manage-
ment is responsive to changes in the patient’s condition (Toussaint
2018). The management approach also depends on availability of
equipment and local expertise, which may vary substantially at a
global level (Toussaint 2018). It is not yet clear what people with
NMD and their caregivers value when considering the choice of
cough augmentation technique, and this warrants further investi-
gation.
In order to advocate for the best and most appropriate treatment
of people with chronic NMD in different sociogeographical con-
texts, it is necessary to first determine which cough augmentation
technique/s, dosages and frequencies are effective and safe for use
in people with chronic NMD, using clinically relevant outcome
measures.
O B J E C T I V E S
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To assess the efficacy and safety of cough augmentation techniques
in adults and children with chronic NMD and respiratory muscle
weakness.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs), quasi-RCTs
and randomised cross-over trials. Quasi-randomised trials are
those in which participants are allocated using methods that are
partly systematic, such as by case record number, date of birth, or
alternation. We will include studies reported as full text and those
published as abstract only. There will be no language restrictions.
Types of participants
We will include adults, adolescents and children with a diagnosis
of any chronic NMD with respiratory muscle weakness.
Owing to age-related changes in respiratory anatomy and phys-
iology, we plan to stratify participants according to age. For the
purposes of this review, ’infants’ will refer to children under the
age of one year; ’children’ from one to 13 years of age; and ’ado-
lescents/adults’ over the age of 13 years. We have chosen 13 years
as the cut-off for children versus adolescents/adults, as respiratory
system development continues until about 12 years of age.We will
also stratify participants according to whether the intervention is
’rescue’ therapy (i.e. intercurrent acute chest infection in a person
with chronic NMD) or maintenance therapy, where possible.
We will exclude participants with the following comorbidities/
characteristics.
1. Amyotrophic lateral sclerosis/motor neuron disease (ALS/
MND), which is the focus of another review.
2. Acute NMD with likelihood of resolution, e.g. Guillain-
Barré syndrome.
3. Spinal cord injuries.
4. Neonates in the first month of life, as they are
pathophysiologically and anatomically a unique patient group
warranting a separate review.
Types of interventions
We will include trials comparing any cough augmentation tech-
nique or combination of techniques, whether provided as main-
tenance therapy or for treatment of intercurrent respiratory tract
infection, with no treatment (unassisted cough), alternative cough
augmentation techniques, or combinations thereof. We will allow
co-interventions provided that they are provided to each group
equally.
Cough augmentation techniques will include, but will not be lim-
ited to:
1. manual or mechanical insufflation;
2. breath/air stacking;
3. glossopharyngeal breathing;
4. mechanical insufflation-exsufflation (MI-E);
5. mechanical exsufflation;
6. and manually-assisted cough (MAC).
Types of outcome measures
In formulating primary and secondary outcome measures, we will
differentiate between cough augmentation techniques used for res-
cue therapy (e.g. during intercurrent respiratory exacerbations)
and maintenance management.
In addition to the formal outcome measures listed below, we will
informally include any valid measure of economic comparison
between cough augmentation techniques relative to health out-
comes.
The outcomes listed here are not eligibility criteria for this review,
but are outcomes of interest within whichever studies we include.
Primary outcomes
1. Number of unscheduled hospital admissions for episodes of
acute respiratory exacerbations over one year
2. Duration of hospital stay (days) for ’rescue’ use.
Secondary outcomes
1. PCF measured before and after intervention for ’rescue’ use
and measured over the medium term (between three months and
one year) and long term (one year and longer) for maintenance
use.
2. Any adverse events, including, but not limited to:
pneumothorax, rib fractures, lung injury, aerophagia/abdominal
distension, and death.
3. Measures of gaseous exchange (e.g. oxygenation (PaO2/
SaO2); expired carbon dioxide (ETCO2)) measured before and
after the intervention for ’rescue’ use, and measured over the
medium term (between three months and one year) and long
term (one year and longer) for maintenance use.
4. Pulmonary function measured by forced expiratory volume
in one second (FEV1), forced vital capacity (FVC), vital capacity
(VC) and peak expiratory flow rate (PEFR), over the short term
(less than three months); medium term (between three months
and one year) and long term (one year and longer). Where
possible, we will present values as percentages predicted
according to age, gender and height; or as Global Lung Function
Initiative multi-ethnic norm-referenced Z score values (Quanjer
2012).
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5. Quality of life measured by any validated measure over the
medium term (between three months and one year) and long
term (one year and longer) for maintenance use.
6. Validated measures of function, including measures of
perceived exertion, exercise tolerance and motor function
measured over the medium term (between three months and one
year) and long term (one year and longer) for maintenance use.
7. Participant preference for specific cough augmentation
techniques, measured as a proportion or percentage of the
sample.
Search methods for identification of studies
Electronic searches
The Information Specialist will search the following databases.
1. Cochrane Neuromuscular Specialised Register via the
Cochrane Register of Studies (CRS-Web).
2. Cochrane Central Register of Controlled Trials
(CENTRAL) via the Cochrane Register of Studies (CRS-Web).
3. MEDLINE (1946 onwards).
4. Embase (1974 onwards).
5. CINAHL (1937 onwards).
The draft MEDLINE strategy is in Appendix 1. We will use this
as the basis for search strategies for the other databases listed.
We will also conduct a search of the US National Institutes for
Health Clinical Trials Registry, www.ClinicalTrials.gov, and the
WHO International Clinical Trials Registry Platform (ICTRP;
apps.who.int/trialsearch/). We will search all databases from their
inception to the present, and we will impose no restriction by
language of publication, or by publication status (abstract only,
’in press’, ’grey’ literature, full text, etc.).
Searching other resources
We will search reference lists of all primary studies and review ar-
ticles for additional references. We will search relevant manufac-
turers’ websites for trial information. We will also search for errata
or retractions from included studies.
Data collection and analysis
Selection of studies
Two review authors (BM, AH)will independently screen titles and
abstracts of all the studies we identify as a result of the search for
inclusion, and code them as ’retrieve’ (eligible or potentially eligi-
ble/unclear) or ’do not retrieve’.We will retrieve the full-text study
reports/publication, and two review authors (BM, LC) will inde-
pendently screen the full text and identify studies for inclusion,
and will identify and record reasons for exclusion of the ineligible
studies. We will resolve any disagreement through discussion or, if
required, we will consult a third person as arbiter (MZ). We will
identify and exclude duplicates and collate multiple reports of the
same study so that each study rather than each report is the unit
of interest in the review. We will record the selection process in
sufficient detail to complete a PRISMA flow diagram and ’Char-
acteristics of excluded studies’ table.
Data extraction and management
We will use a data extraction form for study characteristics and
outcome data which has been piloted on at least one study in the
review. One review author (BM) will extract study characteristics
from included studies . We will extract data on:
1. Study design and setting;
2. Characteristics of participants (e.g. disease severity and age);
3. Eligibility criteria;
4. Intervention details;
5. Outcomes assessed;
6. Source(s) of study funding;
7. Any conflicts of interest among investigators.
Two review authors (AH; LC) will independently extract outcome
data from included studies. We will note in the ’Characteristics
of included studies’ table if outcome data were not reported in a
usable way, resolving disagreements by consensus or by involving
a third person if necessary (MT). One review author (BM) will
transfer data into Review Manager 5 (RevMan 2014). A second
author will check the outcome data entries (AH). Another review
author (MZ) will spot-check study characteristics for accuracy
against the trial report.
When reports require translation, the translator will extract data
directly using a data extraction form, or authors will extract data
from the translation provided.Where possible a review author will
check numerical data in the translation against the study report.
Assessment of risk of bias in included studies
Two review authors (BM; AH) will independently assess risks of
bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2017).
We will make summary assessments of the risk of bias for each im-
portant outcome (across domains) within and across studies com-
paring the same interventions. We will resolve any disagreements
by discussion or by involving another author (LC). We will assess
the risk of bias according to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
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7. Other bias.
We will grade each potential source of bias as high, low or un-
clear, and provide a quote from the study report together with a
justification for our judgement in the ’Risk of bias’ table. We will
summarise the ’Risk of bias’ judgements across different studies for
each of the domains listed. We will consider blinding separately
for different key outcomes where necessary. Where information
on risk of bias relates to unpublished data or correspondence with
an author, we will note this in the ’Risk of bias’ table.
When considering treatment effects, we will take into account the
risk of bias for the studies that contribute to that outcome.
Assessment of bias in conducting the systematic
review
We will conduct the review according to this published protocol,
and will report any deviations from it in the ’Differences between
protocol and review’ section.
Measures of treatment effect
We will analyse all data for ’rescue’ and maintenance use of cough
augmentation techniques separately.We will analyse dichotomous
data as risk ratios (RRs) and continuous data as mean difference
(MD), or standardised mean difference (SMD) for results across
studieswith outcomes that are conceptually the same butmeasured
in different ways. Where standard errors of the means (SEMs) are
reported, we will convert these to standard deviations (SDs) where
possible. We will enter data presented as a scale with a consistent
direction of effect.
We will calculate a Peto odds ratio (Peto OR) and corresponding
95% confidence interval (CI) for rare adverse events. In the case of
statistically significant results, we will calculate the risk difference
(RD) and95%CI and the number needed to treat for an additional
beneficial outcome (NNTB) or for an additional harmful outcome
(NNTH) as appropriate.
Wewill undertakemeta-analyses only where this ismeaningful, i.e.
if the treatments, participants and the underlying clinical question
are similar enough for pooling to be meaningful. We will report
separately types of cough augmentation techniques and different
underlying conditions which cannot be pooled (if the number of
trials permits).
Wewill describe skewed data reported asmedians and interquartile
ranges.
Unit of analysis issues
We will include only first-period data from cross-over trials
(Higgins 2011). Long-term studies with multiple repeated mea-
sures of outcome may be included, in which case we will define
outcomes based on the specified time points (Higgins 2011).
Where multiple trial arms are reported in a single trial, we will
include only the treatment arms relevant to the review topic. If two
comparisons (e.g. treatment A versus no treatment and treatment
B versus no treatment) are combined in the samemeta-analysis, we
will follow guidance in Section 16.5.4 of the Cochrane Handbook
for Systematic Reviews of Interventions to avoid double-counting (
Higgins 2011).Our preferred approachwill be to halve the control
group.
Dealing with missing data
We will contact investigators or study sponsors in order to verify
key study characteristics and obtain missing numerical outcome
data where possible (e.g. when a study is available as an abstract
only). Where this is not possible, we will consider the studies
adequate if more than 85% of the participants are included in
the outcome analysis or if fewer participants were analysed but
sufficient measures were taken to ensure or demonstrate that this
did not bias the results. Where this is not clear, we will conduct
an intention-to-treat analysis from extrapolated data. If we suspect
that missing datamay have introduced serious bias, wewill explore
the impact of including such studies in the overall assessment of
results by a sensitivity analysis.
Assessment of heterogeneity
We will use the I2 statistic to measure heterogeneity among the
trials in each analysis. We will avoid the use of absolute cut-off
values, but will interpret I2 in relation to the size and direction
of effects and strength of evidence for heterogeneity (e.g. P value
from the Chi2 test, or confidence interval for I2).
We will use the rough guide to interpretation as outlined in Chap-
ter 9 of the Cochrane Handbook for Systematic Reviews of Interven-
tions (Deeks 2017), as follows:
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
If we identify substantial unexplained heterogeneity we will report
it and explore possible causes by prespecified subgroup analysis.
Assessment of reporting biases
If we are able to pool more than 10 trials, we will create and
examine a funnel plot to explore possible small-study biases.
Data synthesis
We will use a random-effects model, as this is more conservative,
and explore possible causes of heterogeneity by subgroup analyses if
there are sufficient studies to do so.Wewill conduct meta-analyses
where there is minimal clinical or methodological heterogeneity.
Where we cannot pool data, we will report the results in narrative
form.
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If the review includes more than one comparison which cannot be
included in the same analysis, we will report the results for each
comparison separately.
’Summary of findings’ table
We will create separate ’Summary of findings’ tables for ’rescue’
and maintenance use of cough augmentation techniques, using
GRADEpro GDT software, and will present the following out-
comes.
1. Number of unscheduled hospital admissions for episodes of
respiratory exacerbations over the medium term (between three
months and one year) and long term (one year and longer) for
maintenance use.
2. Duration of hospital stay (days) for ’rescue’ use.
3. PCF measured before and after intervention for ’rescue’ use
and measured over the medium term (between three months and
one year) and long term (one year and longer) for maintenance
use.
4. Any adverse events (’rescue’ and maintenance).
5. Quality of life measured by any validated measure over the
medium term (between three months and one year) and long
term (one year and longer) (maintenance use).
6. Participant preference (’rescue’ and maintenance).
Two review authors (BM and AH) will independently assess the
quality of the body of evidence (studies that contribute data for
the prespecified outcomes) using the five GRADE considerations
(study limitations, consistency of effect, imprecision, indirectness
and publication bias). We will use methods and recommenda-
tions described in Chapters 11 and 12 of the Cochrane Hand-
book for Systematic Reviews of Interventions (Schünemann 2017a;
Schünemann 2017b). We will resolve any disagreements by dis-
cussion or by involving another author (LC). We will assess trial
quality (certainty of the evidence) according to the GRADE cri-
teria. We will consider RCTs as high-quality evidence if the five
factors above are not present to any serious degree, but may down-
grade the quality to moderate, low or very low. We will downgrade
evidence once if a quality consideration is serious and twice if very
serious. We will justify all decisions to downgrade or upgrade the
quality of studies using footnotes, and will make comments to aid
readers’ understanding of the review where necessary.
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses if possible.
1. Infants versus children.
2. Children versus adolescents/adults.
We will use the following outcomes in subgroup analyses.
1. Number of hospital admissions over one year (for
maintenance use).
2. Duration of hospital stay (days) for ’rescue’ use.
We will use the formal test for subgroup interactions in RevMan
5 (RevMan 2014).
Sensitivity analysis
We plan to carry out the following sensitivity analyses.
1. Repeat the analysis excluding unpublished studies (if there
are any).
2. Repeat the analysis excluding studies at high risk of bias
(e.g. randomised versus quasi-randomised). We will rate studies
at overall high risk of bias if there is a high risk of bias for one or
more key domains (Higgins 2017)).
3. If there is one or more very large studies, we will repeat the
analysis excluding them to determine to what extent they
dominate the results.
4. Repeat the analysis using different statistical models (fixed-
effect versus random-effects).
Reaching conclusions
We will base our conclusions only on findings from the quantita-
tive or narrative synthesis of included studies for this review. We
will avoid making recommendations for practice and our impli-
cations for research will suggest priorities for future research and
outline what the remaining uncertainties are in the area.
A C K N OW L E D G E M E N T S
The Information Specialist of Cochrane Neuromuscular, Angela
Gunn, developed the search strategy in consultation with the re-
view authors.
The Methods section of this protocol is based on a template de-
veloped by the Cochrane Neuromuscular Disease Group from an
original created by the Cochrane Airways Group.
This project was supported by the National Institute for Health
Research, via Cochrane Infrastructure funding to Cochrane Neu-
romuscular. The views and opinions expressed therein are those of
the authors and do not necessarily reflect those of the Systematic
Reviews Programme, NIHR, NHS or the Department of Health.
Cochrane Neuromuscular is also supported by the MRC Centre
for Neuromuscular Disease.
7Cough augmentation techniques for people with chronic neuromuscular disorders (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
R E F E R E N C E S
Additional references
Albuali 2007
Albuali WH, Singh RN, Fraser DD, Seabrook JA, Kavanagh
BP, Parshuram CS, et al. Have changes in ventilation
practice improved outcome in children with acute lung
injury?. Pediatric Critical Care Medicine 2007;8(4):324–30.
Anderson 2005
Anderson JL, Hasney KM, Beaumont NE. Systematic
review of techniques to enhance peak cough flow and
maintain vital capacity in neuromuscular disease: the case
for mechanical insufflation-exsufflation. Physical Therapy
Reviews 2005;10(1):25–33.
Bach 1996
Bach JR, Saporito LR. Criteria for extubation and
tracheostomy tube removal for patients with ventilatory
failure. A different approach to weaning. Chest 1996;110
(6):1566–71.
Bach 1997
Bach JR, Ishikawa Y, Kim H. Prevention of pulmonary
morbidity for patients with Duchenne muscular dystrophy.
Chest 1997;112(4):1024–8.
Bach 2003
Bach JR. Mechanical insufflation/exsufflation: has it come
of age? A commentary. European Respiratory Journal 2003;
Vol. 21, issue 3:385–6. [PUBMED: 12661989]
Bach 2007
Bach JR, Bianchi C, Vidigal-Lopes M, Turi S, Felisari G.
Lung inflation by glossopharyngeal breathing and “air
stacking” in Duchenne muscular dystrophy. American
Journal of Physical Medicine & Rehabilitation 2007;86(4):
295–300. [PUBMED: 17413542]
Bianchi 2008
Bianchi C, Baiardi P. Cough peak flows: standard values
for children and adolescents. American Journal of Physical
Medicine & Rehabilitation 2008;87(6):461–7. [PUBMED:
18496248]
Boitano 2006
Boitano LJ. Management of airway clearance in
neuromuscular disease. Respiratory Care 2006;51(8):913-
22; discussion 922-4. [PUBMED: 16867201]
Bott 2009
Bott J, Blumenthal S, Buxton M, Ellum S, Falconer
C, Garrod R, et al. Guidelines for the physiotherapy
management of the adult, medical, spontaneously breathing
patient. Thorax 2009;64 Suppl 1:i1–51. [PUBMED:
19406863]
Chatwin 2018
Chatwin M, Toussaint M, Goncalvez MR, Sheers N,
Mellies U, Gonzales-Bermejo J, et al. Airway clearance
techniques in neuromuscular disorders: a state of the art
review. Respiratory Medicine 2018;136:98–110.
Deeks 2017
Deeks JJ, Higgins JP, Altman DG, editor(s). Chapter
9: Analysing data and undertaking meta-analyses.
In: Higgins JP, Churchill R, Chandler J, Cumpston
MS, editor(s). Cochrane Handbook for Systematic
Reviews of Interventions Version 5.2.0 (updated June
2017). Cochrane, 2017. Available from www.training.
cochrane.org/handbook.
Dohna-Schwake 2006
Dohna-Schwake C, Ragette R, Teschler H, Voit T, Mellies
U. IPPB-assisted coughing in neuromuscular disorders.
Pediatric Pulmonology 2006;41(6):551–7. [PUBMED:
16617451]
Douglas 1981
Douglas NJ, Drummond GB, Sudlow MF. Breathing at low
lung volumes and chest strapping: a comparison of lung
mechanics. Journal of Applied Physiology 1981;50:650–7.
Fauroux 2008
Fauroux B, Guillemot N, Aubertin G, Nathan N, Labit
A, Clement A, et al. Physiologic benefits of mechanical
insufflation-exsufflation in children with neuromuscular
diseases. Chest 2008;133(1):161–8. [PUBMED:
18071020]
Finder 2004
Finder JD, Birnkrant D, Carl J, Farber HJ, Gozal D,
Iannaccone ST, et al. Respiratory care of the patient with
Duchenne muscular dystrophy: ATS consensus statement.
American Journal of Respiratory and Critical Care Medicine
2004;170(4):456–65. [PUBMED: 15302625]
Finder 2010
Finder JD. Airway clearance modalities in neuromuscular
disease. Paediatric Respiratory Reviews 2010;11(1):31–4.
[PUBMED: 20113989]
Gattinoni 2003
Gattinoni L, Carlesso E, Cadringher P, Valenza F, Vagginelli
F, Chiumello D. Physical and biological triggers of
ventilator-induced lung injury and its prevention. European
Respiratory Journal 2003;22(47 Suppl):15s–25s.
Gattinoni 2010
Gattinoni L, Protti A, Caironi P, Carlesso E. Ventilator-
induced lung injury: the anatomical and physiological
framework. Critical Care Medicine 2010;38(10 Suppl):
S539–48.
Gozal 2000
Gozal D. Pulmonary manifestations of neuromuscular
disease with special reference to Duchenne muscular
dystrophy and spinal muscular atrophy. Pediatric
Pulmonology 2000;29(2):141–50. [PUBMED: 10639205]
Higgins 2011
Higgins JP, Green S, editor(s). Cochrane Handbook
for Systematic Reviews of Interventions Version 5.1.0
(updated March 2011). The Cochrane Collaboration,
2011. Available from www.handbook.cochrane.org.
8Cough augmentation techniques for people with chronic neuromuscular disorders (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Higgins 2017
Higgins J, Altman DG, Sterne JA, editor(s). Chapter 8:
Assessing risk of bias in included studies. In: Higgins
JP, Churchill R, Chandler J, Cumpston MS, editor
(s). Cochrane Handbook for Systematic Reviews of
Interventions Version 5.2.0 (updated June 2017). Cochrane,
2017. Available from www.training.cochrane.org/
handbook.
Homnick 2007
Homnick DN. Mechanical insufflation-exsufflation for
airway mucus clearance. Respiratory Care 2007;52(10):
1296-305; discussion 1306-7. [PUBMED: 17894900]
Hull 2012
Hull J, Aniapravan R, Chan E, Chatwin M, Forton J,
Gallagher J, et al. British Thoracic Society guideline for
respiratory management of children with neuromuscular
weakness. Thorax 2012;67(1):1–40.
Iannaccone 2007
Iannaccone ST. Modern management of spinal muscular
atrophy. Journal of Child Neurology 2007;22(8):974–8.
[PUBMED: 17761652]
Kang 2000
Kang SW, Bach JR. Maximum insufflation capacity:
vital capacity and cough flows in neuromuscular disease.
American Journal of Physical Medicine & Rehabilitation
2000;79(3):222–7. [PUBMED: 10821306]
Leiner 1963
Leiner GC, Brramowitz S, Small MJ, Stenby VB, Lewis
WA. Expiratory peak flow rate. Standard values for normal
subjects. Use as a clinical test of ventilatory function.
American Review of Respiratory Disease 1963;88:644–51.
Marques 2014
Marques TB, Neves J de C, Portes LA, Salge JM, Zanoteli
E, Reed UC. Air stacking: effects on pulmonary function
in patients with spinal muscular atrophy and in patients
with congenital muscular dystrophy. Jornal Brasileiro de
Pneumologia 2015;40(5):528–34.
McCool 2006
McCool FD, Rosen MJ. Nonpharmacologic airway
clearance therapies: ACCP evidence-based clinical practice
guidelines. Chest 2006;129(1 Suppl):250S–9S. [PUBMED:
16428718]
Morrow 2013
Morrow B, Zampoli M, Van Aswegen H, Argent
A. Mechanical insufflation-exsufflation for people
with neuromuscular disorders. Cochrane Database of
Systematic Reviews 2013, Issue 12. DOI: 10.1002/
14651858.CD010044.pub2
Nygren-Bonnier 2009
Nygren-Bonnier M, Markström A, Lindholm P, Mattsson
E, Klefbeck B. Glossopharyngeal pistoning for lung
insufflation in children with spinalmuscular atrophy type II.
Acta Paediatrica 2009;98:1324-8.
Panitch 2009
Panitch HB. The pathophysiology of respiratory impairment
in pediatric neuromuscular diseases. Pediatrics 2009;123
Suppl 4:S215–8. [PUBMED: 19420146]
Papastamelos 1996
Papastamelos C, Panitch HB, Allen JL. Chest wall
compliance in infants and children with neuromuscular
disease. American Journal of Respiratory and Critical Care
Medicine 1996;154(4 Pt 1):1045–8. [PUBMED: 8887605]
Quanjer 2012
Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL,
Culver BH, et al. ERS Globalet al Lung Function Initiative.
Multi-ethnic reference values for spirometry for the 3-95-
yr age range: the global lung function 2012 equations.
European Respiratory Journal 2012;40(6):1324–43.
RevMan 2014 [Computer program]
The Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager (RevMan). Version 5.3. Copenhagen:
The Nordic Cochrane Centre, The Cochrane Collaboration,
2014.
Rokadia 2015
Rokadia HK, Adams JR, McCarthy K, Aboussouan LS,
Mireles-Cabodevila E. Cough augmentation in a patient
with neuromuscular disease. Annals of the American Thoracic
Society 2015;12(12):1888–91.
Rosière 2009
Rosière J, Vader JP, Cavin MS, Grant K, Larcinese A,
Voellinger R, et al. Appropriateness of respiratory care:
evidence-based guidelines. Swiss Medical Weekly 2009;139
(27-28):387–92.
Saharan 2010
Saharan S, Lodha R, Kabra SK. Management of acute lung
injury/ARDS. Indian Journal of Pediatrics 2010;77(11):
1296–302.
Schünemann 2017a
Schünemann HJ, Oxman AD, Higgins JP, Vist GE,
Glasziou P, Akl E, et al. Chapter 11: Completing ’Summary
of findings’ tables and grading the confidence in or
quality of the evidence. In: Higgins JP, Churchill R,
Chandler J, Cumpston MS, editor(s). Cochrane Handbook
for Systematic Reviews of Interventions Version 5.2.0
(updated June 2017). Cochrane, 2017. Available from
www.training.cochrane.org/handbook.
Schünemann 2017b
Schünemann HJ, Oxman AD, Vist GE, Higgins JP, Deeks
JJ, Glasziou P, et al. Chapter 12: Interpreting results
and drawing conclusions. In: Higgins JP, Churchill R,
Chandler J, Cumpston MS, editor(s). Cochrane Handbook
for Systematic Reviews of Interventions Version 5.2.0
(updated June 2017). Cochrane, 2017. Available from
www.training.cochrane.org/handbook.
Sivasothy 2001
Sivasothy P, Brown L, Smith IE, Shneerson JM. Effect
of manually assisted cough and mechanical insufflation
on cough flow of normal subjects, patients with chronic
9Cough augmentation techniques for people with chronic neuromuscular disorders (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
obstructive pulmonary disease (COPD), and patients with
respiratory muscle weakness. Thorax 2001;56(6):438–44.
[PUBMED: 11359958]
Suri 2008
Suri P, Burns SP, Bach JR. Pneumothorax associated with
mechanical insufflation-exsufflation and related factors.
American Journal of Physical Medicine & Rehabilitation
2008;87(11):951–5. [PUBMED: 18617862]
Toussaint 2018
Toussaint M, Chatwin M, Gonzalez J, Berlowitz DJ, the
ENMC Respiratory Therapy Consortium. 228th ENMC
international workshop: airway clearance techniques in
neuromuscular disorders 3-5 March, 2017, Naarden, The
Netherlands. Neuromuscular Disorders 2018;28:289–98.
Trebbia 2005
Trebbia G, Lacombe M, Fermanian C, Falaize L, Lejaille
M, Louis A, et al. Cough determinants in patients
with neuromuscular disease. Respiratory Physiology and
Neurobiology 2005;146(2-3):291–300.
Tzeng 2000
Tzeng AC, Bach JR. Prevention of pulmonary morbidity for
patients with neuromuscular disease. Chest 2000;118(5):
1390–6. [PUBMED: 11083691]
Vianello 2004
Vianello A, Arcaro G, Gallan F, Ori C, Bevilacqua M.
Pneumothorax associated with long-term non-invasive
positive pressure ventilation in Duchenne muscular
dystrophy. Neuromuscular Disorders 2004;14(6):353–5.
Wang 2007
Wang CH, Finkel RS, Bertini ES, Schroth M, Simonds A,
Wong B, et al. Participants of the International Conference
on SMA Standard of Care. Consensus statement for
standard of care in spinal muscular atrophy. Journal of Child
Neurology 2007;22(8):1027–49.
Wang 2010
Wang CH, Bonnemann CG, Rutkowski A, Sejersen T,
Bellini J, Battista V, et al. Consensus statement on standard
of care for congenital muscular dystrophies. Journal of Child
Neurology 2010;25(12):1559–81. [PUBMED: 21078917]
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A P P E N D I C E S
Appendix 1. MEDLINE (OvidSP) draft search strategy
Database: Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and
Ovid MEDLINE(R) <1946 to Present>
Search Strategy:
--------------------------------------------------------------------------------
1 randomized controlled trial.pt. (455306)
2 controlled clinical trial.pt. (92216)
3 randomi#ed.ti,ab. (520311)
4 placebo.ab. (186900)
5 drug therapy.fs. (1998447)
6 randomly.ab. (286114)
7 trial.ab. (420183)
8 groups.ab. (1769782)
9 or/1-8 (4153256)
10 exp animals/ not humans.sh. (4432422)
11 9 not 10 (3588435)
12 (assist* adj2 cough*).mp. (227)
13 (breath stack* or air stack*).mp. (62)
14 glossopharyngeal breath*.mp. (60)
15 frog breath*.mp. (5)
16 (mechanical adj4 (insufflation or exsufflation)).mp. (132)
17 manual insufflation.mp. (7)
18 16 or 17 (139)
19 (breath* or resp*).mp. (5770668)
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20 18 and 19 (119)
21 or/12-15,20 (394)
22 11 and 21 (69)
C O N T R I B U T I O N S O F A U T H O R S
BM wrote the protocol; MZ, AH, LC, AA and MT all contributed to the final draft of the protocol and have agreed to its contents
and their role in the final review.
D E C L A R A T I O N S O F I N T E R E S T
BM: BM has no particular conflict of interest to declare in respect of this protocol. She received an unconditional donation of
consumables and a Nippy mechanical In-exsufflation device for an ongoing clinical trial of MI-E from Bakoni Medical company. BM
is principal investigator of a trial which may be eligible for inclusion in later versions of this review, in which case she will recuse herself
from that data extraction and analysis.
AH: Received an unconditional donation of equipment and consumables for a clinical trial of MI-E (currently underway) from Bakoni
Medical company. She is the student investigator of a trial which may be eligible for inclusion in later versions of this Review, in which
case she will recuse herself from that data extraction and analysis.
AA: AA is a specialist (paediatric critical care) physician and manages patients with a variety of conditions. He has no particular conflicts
of interest to declare in respect of this protocol.
MZ: MZ is a specialist (paediatric pulmonology) and manages patients with a variety of conditions, including a range of NMDs. He
has no particular conflicts of interest to declare in respect of this protocol.
LC: No conflicts to declare
MT: No conflicts to declare
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N O T E S
This review will partially supersede Mechanical insufflation-exsufflation for people with neuromuscular disorders (Morrow 2013).
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